Developing novel anti-cancer therapies
RIANA Therapeutics has been nominated as a finalist in the Spin-off category of the Austrian Gründungspreis PHÖNIX 2026!
Initiatives like PHÖNIX help make visible how research can translate into real-world impact, something essential for the development of the biotech ecosystem in Austria.
The winners will be announced in Vienna on 12 March.
Copyright photo: Gründungspreis Phönix © Arina Tkacheva
Time is rushing – especially in a buzzing and vibrant field like biotech.
Three years ago, RIANA Therapeutics started with a bold scientific vision and the belief that small, focused teams can tackle big challenges. Today, we are proud of how far we’ve come — from early scientific validation to advancing our STAT5 program with growing clarity and conviction.
At the same time, we are deeply aware of how much further we have to go. Drug development is a marathon, not a sprint. And we embrace that journey with resilience, curiosity, and determination.
None of this would exist without an exceptional team. The dedication, sharp thinking, persistence, and trust within this group are what truly define RIANA.
Building this together has been the most humbling and rewarding experience. ❤️
Here’s to the science, the patients we aim to serve, and the exciting years ahead.
— The RIANA Team
| 04.-05. March | Sachs European Life Science CEO Forum, Zurich |
| 23.-25. March | BioSpring & RESI, Lisboa |
| 27.-28. April | BioVaria, Munich |
| 03.-05. May | Swiss Biotech Days, Basel |
| 04.-06. May | BioEquityEurope, Prague |
We look forward to networking with venture capital, business angels and industry leaders, discussing how RIANA’s STAT5 inhibitor program is paving the way for new treatments in oncology. If you’ll be there, we’d love to connect!
From November 3–5, the RIANA team was delighted to participate in BioEurope 2025, hosted this year in our beautiful home city of Vienna.
It was an inspiring few days filled with engaging conversations, valuable new connections, and the opportunity to reconnect with many familiar faces from the biotech community.
A special highlight was Anna’s pitch on Wednesday, where she presented our STAT5 program and introduced RIANA’s current seed investment round.
We’re proud to be part of the vibrant Austrian biotech community, and deeply appreciate the professional and charming organization and support by Life Science Austria – LISA — who made this exceptional event run so smoothly.
Thank you to everyone who contributed to such an energizing and productive conference experience!
On September 25, 2025, RIANA Therapeutics took part in the Prague.bio Conference 2025, one of Central and Eastern Europe’s leading events for the biotechnology and life sciences community.
The conference brought together founders, investors, scientists, and innovation leaders from across the region — all sharing a common goal: to strengthen and connect the CEE biotech ecosystem.
We are proud to announce that RIANA Therapeutics was awarded the 1st Prize in the Prague.bio Pitch Competition 🥇, recognizing our innovative work on developing novel STAT5 inhibitors for the treatment of acute myeloid leukemia (AML).
The event featured outstanding talks from keynote speakers Hannah Nelson, Philipp Kukura, and Wojciech Nowak, and was perfectly moderated by Michala Hergetová, whose enthusiasm and professionalism set a great tone for the day.
We extend our warm congratulations to the other winners, HeartBeat.bio AG and Nanoflexion, and our sincere thanks to the entire Prague.bio team for organizing such a well-curated and inspiring event.
We left Prague energized and deeply motivated by the spirit of collaboration and innovation driving biotech in Central Europe.
We’re already looking forward to BioEquity Europe 2026, which will take place in Prague next May – another great opportunity to strengthen international ties and showcase the potential of our region’s biotech startups.
Together we go further!
On Saturday morning, October 4, the RIANA team joined the Krebsforschungslauf (Cancer Research Run) at the Medical University of Vienna.
The weather was perfect, the atmosphere uplifting, and the event beautifully organized by the MedUni Vienna team. We truly enjoyed running together for such a meaningful cause – with every single euro directly supporting cancer research.
We’re keeping our fingers crossed that the organizers will reach their ambitious goal of 30,000 laps around the Altes AKH university campus and the distance run, because if they do, donations will be increased by an additional €17,500!
We are proud to have contributed 26 laps (26 miles) to this year’s total, and even prouder to support the scientists and initiatives advancing cancer research in Austria with our feet, but also our own work at RIANA.
We’ll definitely be back next year, on October 10, 2026, to celebrate the 20th anniversary of the Krebsforschungslauf!
We look forward to networking with venture capital, business angels and industry leaders, discussing how RIANA’s STAT5 inhibitor program is paving the way for new treatments in oncology. If you’ll be there, we’d love to connect!
Vienna, Nov 9 2024
What an honor! We are proud to share that RIANA Therapeutics has been named one of Austria’s Top 20 Most Innovative Start-ups by Trend. magazine! We’re truly honored by this recognition. A big thank you to the jury for their support and belief in our vision.
Thank you to everyone who’s been part of this journey – our incredible RIANA team, our exceptional partners, and the wider community supporting us in creating a healthier future.
Read the whole article here
Dec 4, 2024 | London, UK
Meet our CBO, Christine Ruckenbauer, in person on December 4 or online afterwards, December 4-5.
The RESI (Redefining Early Stage Investments) event in London is the perfect platform for early-stage biotech startups like RIANA Therapeutics to connect with potential investors, explore funding opportunities, and showcase our innovative approach to advancing cancer therapies.
We look forward to networking with industry leaders and discussing how RIANA’s STAT5 inhibitor program is paving the way for new treatments in oncology. If you’ll be there, we’d love to connect!
In a recent article for the Brutkasten magazine RIANA Therapeutics CEO Anna Orlova, Christopher Trummer (Celeris Therapeutics), and Peter Llewellyn-Davies (President Biotech-Austria) discuss the challenges and opportunities facing the biotech industry.
“It is always difficult to explain to people who are not familiar with the life science industry what our challenges are and why we are not yet making sales.” says Anna Orlova.
“Fact is, Biotech is not easy. But it is also a fact that we do something for the health of humanity and that we do it with passion. And the fact is that biotech is one of the most innovative industries in Austria and makes a significant contribution to achieving one of the highest research and development rates in the EU. Austria took third place in the EU, and the trend is rising.”, says Peter Llewellyn-Davies.
Link: Der Brutkasten Magazin
RIANA Therapeutics 